Mutual of America Capital Management LLC trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,877 shares of the company’s stock after selling 835 shares during the quarter. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,536,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $869,000. Achmea Investment Management B.V. increased its position in IDEXX Laboratories by 33.1% in the 2nd quarter. Achmea Investment Management B.V. now owns 7,617 shares of the company’s stock valued at $1,228,000 after acquiring an additional 1,896 shares during the period. Lord Abbett & CO. LLC increased its position in IDEXX Laboratories by 41.3% in the 2nd quarter. Lord Abbett & CO. LLC now owns 107,642 shares of the company’s stock valued at $17,376,000 after acquiring an additional 31,472 shares during the period. USA Financial Portformulas Corp acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $6,355,000. Finally, HWG Holdings LP increased its position in IDEXX Laboratories by 90.3% in the 2nd quarter. HWG Holdings LP now owns 11,131 shares of the company’s stock valued at $1,797,000 after acquiring an additional 5,281 shares during the period. Institutional investors and hedge funds own 87.63% of the company’s stock.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million during the quarter, compared to analysts’ expectations of $492.94 million. During the same quarter in the previous year, the company posted $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Mutual of America Capital Management LLC Reduces Stake in IDEXX Laboratories, Inc. (IDXX)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/mutual-of-america-capital-management-llc-reduces-stake-in-idexx-laboratories-inc-idxx/1675215.html.

IDXX has been the topic of several analyst reports. Stifel Nicolaus restated a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research report on Friday, July 14th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 target price on the stock in a research report on Wednesday, July 19th. CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Friday, July 28th. BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Canaccord Genuity restated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $173.67.

In other IDEXX Laboratories news, Director Rebecca M. Henderson sold 5,156 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total transaction of $790,363.24. Following the completion of the sale, the director now owns 17,274 shares in the company, valued at approximately $2,647,931.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the sale, the chief executive officer now owns 1,043,034 shares of the company’s stock, valued at approximately $161,576,396.94. The disclosure for this sale can be found here. Insiders sold a total of 151,734 shares of company stock valued at $23,436,626 in the last 90 days. 2.77% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.